Sara Samadzadeh

University of Düsseldorf
Country flagGermany

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Background: The objective of this study was to provide evidence from a simple simulation. In patients with focal dystonia, an initial good response to botulinum neurotoxin (BoNT) injections followed by a secondary worsening does not necessarily arise from an antibody-induced secondary treatment failure (NAB-STF), but may stem from a “pseudo”-secondary treatment failure (PSEUDO-STF). Methods: The simulation of the outcome after BoNT long-term treatment was performed in four steps: 1. The effect of the first single BoNT injection (SI curve) was displayed as a 12-point graph, corresponding to the mean improvement from weeks 1 to 12. 2. The remaining severity of the dystonia during the nth injection cycle was calculated by subtracting the SI curve (weighted by the outcome after n − 1 cycles) from the outcome after week 12 of the (n − 1)th cycle. 3. A graph was chosen (the PRO curve), which represents the progression of the severity of the underlying disease during BoNT therapy. 4. The interaction between the outcome during the nth BoNT cycle and the PRO curve was determined. Results: When the long-term outcome after n cycles of BoNT injections (applied every 3 months) was simulated as an interactive process, subtracting the effect of the first cycle (weighted by the outcome after n − 1 cycles) and adding the progression of the disease, an initial good improvement followed by secondary worsening results. This long-term outcome depends on the steepness of the progression and the duration of action of the first injection cycle. We termed this response behavior a “pseudo”-secondary treatment failure, as it can be compensated via a dose increase. Conclusion: A secondary worsening following an initial good response in BoNT therapy of focal dystonia might not necessarily indicate neutralizing antibody induction but could stem from a “PSEUDO”-STF (a combination of good response behavior and progression of the underlying disease). Thus, an adequate dose adaptation must be conducted before diagnosing a secondary treatment failure in the strict sense.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (15)

Sandra Barteit

University Hospital Heidelberg

GERMANY
View details

Francesk Mulita

University Hospital of Patras

GREECE
View details

Tom Luedde

-

GERMANY
View details

Himal Kandel

-

AUSTRALIA
View details

Alvaro Jose Mejia-Vergara

University of Florida

UNITED STATES
View details

Md. Obaidur Rahman

Adjunct Lecturer

St. Luke's International University

JAPAN
View details

Patrick R. Ching

Washington University School of Medicine

UNITED STATES
View details

Frank Konietschke

-

GERMANY
View details

Bernardo F. Sanchez-Dalmau

Hospital Clínic de Barcelona

SPAIN
View details

Hassan Abolhassani

Assistant Professor

Karolinska Institutet

SWEDEN
View details

Rose Bender

Institute for Health Metrics and Evaluation

UNITED STATES
View details

Emmanuel Edwar Siddig

-

NETHERLANDS
View details

Arkadiusz Dziedzic

-

POLAND
View details

Adnan Ansar

Seasonal Teaching Staff

La Trobe University

AUSTRALIA
View details

Joseph Ward

NIHR Clinical Lecturer

University College London Great Ormond Street Institute of Child Health

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.